54453-93-9

Usage

Chemical Properties

Yellow liquid

Upstream product

• 6313-54-8 2-chloroisonicotinic acid, 
• 64-17-5 ethanol 
• 79-37-8 oxalyl dichloride 
• 14906-37-7 ethyl isonicotinate N-oxide 
• 13602-12-5 Isonicotinic acid N-oxide 

Downstream Products

• 629954-85-4 4-ethoxycarbonyl-2-(4-fluoro-2-methylphenyl)pyridine 
• 482375-90-6 ethyl 2-(p-tolyl)pyridine-4-carboxylate 
• 482376-01-2 ethyl 2-(4-methoxyphenyl)isonicotinate 
• 482376-17-0 ethyl 2-[4-(trifluoromethyl)phenyl]isonicotinate 
• 482376-11-4 ethyl 2-(4-fluorophenyl)isonicotinate 
• 92199-59-2 ethyl 2-phenylpyridine-4-carboxylate 
• 482376-14-7 ethyl 2-(4-chlorophenyl)pyridine-4-carboxylate 
• 482375-93-9 ethyl 2-(2-methoxyphenyl)isonicotinate 
• 482376-05-6 ethyl 2-(3,4-dimethoxyphenyl)isonicotinate 
• 427886-03-1 2-(3,4,5-trimethoxyphenyl)isonicotinic Acid 
• 427886-22-4 ethyl 2-(4-chloro-3,5-dimethoxyphenyl)isonicotinate 
• 427886-50-8 Ethyl 2-(3,5-dimethoxy-4-isopropoxyphenyl)isonicotinate 
• 290300-93-5 2-(4-methyl-piperazin-1-yl)-isonicotinic acid ethyl ester 
• 13362-30-6 2-amino-4-ethoxycarbonyl-pyridine 

Relevant academic research and scientific papers

Novel 1,3,4-oxadiazole thioether derivatives targeting thymidylate synthase as dual anticancer/antimicrobial agents

A series of novel 1,3,4-oxadiazole thioether derivatives (compounds 9-44) were designed and synthesized as potential inhibitors of thymidylate synthase (TS) and as anticancer agents. The in vitro anticancer activities of these compounds were evaluated against three cancer cell lines by the MTT method. Among all the designed compounds, compound 18 bearing a nitro substituent exhibited more potent in vitro anticancer activities with IC50 values of 0.7 ± 0.2, 30.0 ± 1.2, 18.3 ± 1.4 μM, respectively, which was superior to the positive control. In the further study, it was identified as the most potent inhibitor against two kinds of TS protein (for human TS and Escherichia coli TS, IC50 values: 0.62 and 0.47 μM, respectively) in the TS inhibition assay in vitro and the most potent antibacterial agents with MIC (minimum inhibitory concentrations) of 1.56-3.13 μg/mL against the tested four bacterial strains. Molecular docking and 3D-QSAR study supported that compound 18 can be selected as dual antitumor/antibacterial candidate in the future study.

4-Pyridyl carbonyl and related compounds as thrips lures: Effectiveness for onion thrips and New Zealand flower thrips in field experiments

On the basis of structural and/or aroma analogies to known thrips (Thysanoptera: Thripidae) lures, 35 compounds (18 pyridine derivatives, 13 benzene derivatives, and 4 other compounds), consisting of both synthetic and naturally occurring compounds, were screened for their ability to bring about increased thrips capture in field experiments using water traps in Canterbury, New Zealand. Most of the thrips caught were New Zealand flower thrips (NZFT) (Thrips obscuratus) or onion thrips (OT) (Thrips tabaci). The greatest increase in capture for NZFT (158 times for ♀ cf. to water control) was for the known lure ethyl nicotinate, a 3-pyridyl ester. Ethyl isonicotinate, the 4-pyridyl regioisomer of ethyl nicotinate, not previously reported as a thrips lure, provided the greatest increases in capture for OT (31 times) of any of the compounds tested, significantly more than ethyl nicotinate. Other 4-pyridyl carbonyl compounds, including ethyl 4-pyridyl ketone, also increased OT capture significantly. The natural floral compound cis-jasmone, which increased trap capture of NZFT (♀ 42 times, ♂ 25 times) but not OT, is reported as a thrips lure for the first time.

INSECT BEHAVIOUR MODIFYING COMPOUNDS

The invention provides methods for controlling thrips populations using thrips-repelling and/or thrips-attracting agents. The agents are derivatives of pyridine. The invention also provides methods of preventing or minimising damage to plants by use of the same.

SUBSTITUTED DIAZABICYCLOHEPTANES AND THEIR USE AS PROTEIN KINASE INHIBITORS

The present invention relates to therapeutic diazobicyclo pyridines and their use in the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis or osteoarthritis, organ transplant, acute transplant or heterograft and homograft rejection, ischemic and reperfusion injury, transplantation tolerance induction, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, lupus, graft vs. host diseases, T -cell mediated hypersensitivity diseases, contact hypersensitivity, delayed-type hypersensitivity, gluten-sensitive enteropathy, Type 1 diabetes, psoriasis, contact dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism,Graves' Disease, Addison's disease, autoimmune polyglandular disease, autoimmune alopecia, pernicious anemia, vitiligo, autoimmune hypopituatarism, Guillain-Barre syndrome, autoimmune diseases, glomerulonephritis, serum sickness, uticaria, respiratory allergies, asthma, hayfever, allergic rhinitis, skin allergies, scleracielma, mycosis fungoides, acute inflammatory responses, acute respiratory distress syndrome, dermatomyositis, alopecia areata, chronic actinic dermatitis, eczema, Behcet's disease, Pustulosis palmoplanteris, Pyoderma gangrenum, Sezary's syndrome, atopic dermatitis, systemic schlerosis, morphea, Type II diabetes and cancers where PKC theta or other PKC-family kinases are activated, overexpressed or facilitate tumor growth or survival of tumor cells, T cell leukemia, thymoma, T and B cell lymphoma, colon carcinoma, breast carcinoma and lung carcinoma or provides resistance to chemotherapeutic drugs.

Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors

The present invention relates to a cyclic urea compound of formula I: as defined herein. The invention is also directed to the process for its preparation, pharmaceutical composition comprising it and its pharmaceutical use, as an inhibitor on a protein kinase. Thus, it is useful for preventing or treating a physiological disorder capable of being modulated by inhibiting the activity of a protein kinase, such as a solid tumor.

NOVEL PIPERIDINE COMPOUND

The present invention provides a novel piperidine compound of the formula [I]: wherein Ring A represents an optionally substituted benzene ring, Ring B represents an optionally substituted benzene ring, R1 represents an optionally substituted alkyl group, an optionally substituted hydroxyl group, etc., or a group of the formula: (a) wherein R11 and R12 are the same or different, and each represents hydrogen atom, a substituted carbonyl group, a substituted sulfonyl group, an optionally substituted alkyl group, etc., R2 represents hydrogen atom, etc., Z represents oxygen atom or a group represented by -N(R3)-, R3 represents hydrogen atom or an alkyl group, etc., R4 represents hydrogen atom or an alkyl group, etc.,or a pharmaceutically acceptable salt thereof.

Chemical compounds

The invention relates to quinazoline derivatives of the formula: [wherein: Y1represents —O—, —S—, —CH2—, —SO—, —SO2—, —NR5CO—, —CONR6—, —SO2NR7—, —NR8SO2— or —NR9— (wherein R5, R6, R8and R9each independently represents hydrogen, alkyl or alkoxyalkyl); R1represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, alkyl, alkoxy, alkylthio, amino or alkylamino. R2represents hydrogen, hydroxy, halogeno, alkyl, alkoxy, trifluoromethyl, cyano, amino or nitro; m is an integer from 1 to 5; R3represents hydroxy, halogeno, alkyl, alkoxy, alkanoyloxy, trifluoromethyl, cyano, amino or nitro; R4represents a group which is or which contains an optionally substituted pyridone, phenyl or aromatic heterocyclic group] and salts thereof; processes for their preparation and pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

Preparation of substituted 2-chloropyridines

A process for the preparation of a substituted 2-chloropyridine derivatives of the formula STR1 in which R1, R2, R3 and R4 represent hydrogen or various other radicals, which comprises reacting a pyridine-1-oxide of the formula STR2 with an aromatic carbonyl chloride in the presence of an inert organic solvent and in the presence of an acid acceptor at a temperature between about -20° C. and 200° C.

Process for the preparation of substituted 2-chloropyridines

A new process has been found for the preparation of substituted 2-chloropyridine derivatives of the formula (I) STR1 wherein R1 to R4 have the meanings as defined in the description. The new process is characterized in that pyridine 1-oxides of the formula II STR2 are reacted with a chlorine-containing phosphoric acid derivative from the series of the chlorophosphoric esters and chlorophosphoramides in the presence of an inert organic solvent and in the presence of an acid acceptor at temperatures between -20° C. and 200° C., and the resulting product is separated further, if appropriate. Compound (I) is known as an intermediate product for medicaments (cf.DE-A 2,812,585) or for insecticidel nitromethylene derivatives (cf. EP-A 163,855).